It is currently Tue May 03, 2016 11:21 pm

News News of ThisIsMS

Site map of ThisIsMS » Forum : ThisIsMS

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.

Daclizumab HYP improves cognition - report

Patients with relapsing-remitting multiple sclerosis (MS) treated with daclizumab high-yield process (HYP) had improved cognitive outcomes at 96 weeks compared with beta interferon, a study presented at the 68th American Academy of Neurology meeting has found...Read more - http://www.ms-uk.org/MSnews
Read more : Daclizumab HYP improves cognition - report | Views : 227 | Replies : 0 | Forum : General Discussion


Aubagio ‘reduces brain volume loss’

Aubagio treatment decreased brain volume loss in patients with relapsing-remitting multiple sclerosis (MS) independent of disability progression, a study presented at the 68th annual American Academy of Neurology meeting concluded...Read more - http://www.ms-uk.org/MSnews
Read more : Aubagio ‘reduces brain volume loss’ | Views : 235 | Replies : 0 | Forum : Aubagio (teriflunomide)


Parkinson's blood test developed

http://www.skynews.com.au/news/national/2016/04/20/parkinson-s-blood-test-developed.html
Although this is not MS specific, what did peak my interest is that it is based on
The researchers measured the activity of mitochondria, 'the small energy powerhouses in cells', in 29 people with Parkinson's and nine without the disease.

'We had expected there would be a reduction in the activity of the Parkinson's cells, but we actually found the reverse,' Prof Fisher said.

'They were four times more active than in the healthy ...
Read more : Parkinson's blood test developed | Views : 208 | Replies : 0 | Forum : General Discussion


NEDA-3, NEDA-4 and my complain

Some years ago, only the clinical relapses were a valid marker of MS evolution. Today MRI has changed the picture and the concept of NEDA (No Evidence of Disease Activity) has appeared.

First it was NEDA-3 (no MRI activity, no relapses and no clinical progression). Currently it is being replaced by NEDA-4 (same three conditions as before plus no brain shrinkage, http://www.novartis.com.ph/newsroom/201 ... 8_001.html)

And now my complain. The ...
Read more : NEDA-3, NEDA-4 and my complain | Views : 250 | Replies : 2 | Forum : General Discussion


Hi from Vicky in London, UK - any advice?

Hi Everyone,

I just stumbled across this website and i am glad i have, been under going tests for MS as I also have CRPS Type 2 AKA RSD (Reflex Sympathetic Dystrophy) and damage to the Ulnar Nerve with Neuropathy in my left arm and elbow.

I had an episode of Optic Neuritis in my right eye reason why i have been undergoing tests for MS, the optic nerve testing came back normal thankfully but ...
Read more : Hi from Vicky in London, UK - any advice? | Views : 280 | Replies : 5 | Forum : Introductions


Interferon ‘does not increase antidepressant use....

Interferon ‘does not increase antidepressant use in MS population’

No correlation between interferon treatment and antidepressant use has been observed in the multiple sclerosis (MS) population, a large-scale study presented at the 68th AAN Annual Meeting reported...Read More - http://www.ms-uk.org/MSnews
Read more : Interferon ‘does not increase antidepressant use.... | Views : 213 | Replies : 0 | Forum : General Discussion


Multiple sclerosis relapses ‘common’ during 20-year period

Regardless of whether the disease is in the progressive phase or not, patients with multiple sclerosis (MS) seem likely to experience relapses for the first time or relapse continuation between the ages of 27 and 47 years according to a new study...Read More - http://www.ms-uk.org/MSnews


The MS-UK Virtual Insight Panel

Find out how you could be a VIP and join our Virtual Insight Panel http://www.ms-uk.org/vip

Image
Read more : The MS-UK Virtual Insight Panel | Views : 193 | Replies : 0 | Forum : General Discussion


Data shows Cladribine benefits persist in RRMS patients

The effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated to last for up to four years after treatment has started, according to the findings of a study presented at the 68th American Academy of Neurology Annual Meeting...Read More - http://www.ms-uk.org/MSnews
Read more : Data shows Cladribine benefits persist in RRMS patients | Views : 217 | Replies : 0 | Forum : General Discussion


Patients ‘tolerate arbaclofen extended-release tabs’

Arbaclofen extended-release tablets (AERT) have proved to have greater tolerability, and similar efficacy and safety, to baclofen in patients with multiple sclerosis (MS), according to randomised trial results reported at the 68th American Academy of Neurology annual Meeting...Read More - http://www.ms-uk.org/MSnews
Read more : Patients ‘tolerate arbaclofen extended-release tabs’ | Views : 206 | Replies : 0 | Forum : General Discussion


 

Login  •  Register


Statistics

Total posts 232089 • Total topics 24792 • Total members 15957


Contact us | Terms of Service